Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 116, Issue 10, 2009, Pages 1307-1314

  Koelewijn, J M ^a   De Haas, M ^a   Vrijkotte, T G M ^a   Van Der Schoot, C E ^a   Bonsel, G J ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Prevention; RhD pregnancy immunisation; Risk factors

Indexed keywords

ERYTHROCYTE ANTIBODY; RHESUS D ANTIBODY;

ADULT; AGE; ANTIBODY SCREENING; ARTICLE; CESAREAN SECTION; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; INSTRUMENTAL DELIVERY; MAJOR CLINICAL STUDY; PERINATAL PERIOD; POSTMATURITY; PRENATAL PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; RHESUS IMMUNIZATION; RISK FACTOR;

ADULT; CASE-CONTROL STUDIES; FEMALE; HEMATOLOGIC AGENTS; HUMANS; ISOANTIBODIES; NETHERLANDS; POSTNATAL CARE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY TRIMESTER, FIRST; PRENATAL CARE; RECURRENCE; RH ISOIMMUNIZATION; RISK FACTORS;

EID: 68849118675     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2009.02244.x     Document Type: Article

References (37)

1. Bowman JM. RhD hemolytic disease of the newborn. N Engl J Med 1998 339 : 1775 7.
2. Levine P, Burnham L, Katzin EM, Vogel P. The role of iso-immunization in the pathogenesis of erythroblastosis fetalis. JAMA 1941 113 : 126 7.
3. Mollison PL, Engelfriet CP, Contreras M. Haemolytic disease of the fetus and the newborn. In : Mollison PL, Engelfriet CP, Contreras M, editors. Blood Transfusion in Clinical Medicine, 10th edn. Oxford : Blackwell Science 1997. pp. 390 424.
4. Daniels G. Blood group antibodies in haemolytic disease of the fetus and newborn. In : Hadly A, Soothill P, editors. Alloimmune Disorders of Pregnancy. Cambridge : University Press 2002. pp. 21 40.
5. Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and the newborn. Blood Rev 2000 14 : 44 61.
6. Kumpel BM. On the immunologic basis of Rh immune globulin (anti-D) prophylaxis. Transfusion 2006 46 : 1652 6.
7. NICE. Routine Antenatal Anti-D Prophylaxis for Women who are Rhesus D Negative. NICE Technology Appraisal Guidance 156. London, UK : National Institute for Health and Clinical Excellence, 2008.
8. Vandenbussche FPHA, Klumper FJ. [Red cell immunisation and pregnancy]. Dutch Society of Obstetrics and Gynaecoly 2002 clinical guideline [Dutch].
9. American College of Obstetricans and Gynecologists. ACOG practice bulletin. Prevention of Rh D alloimmunization. Number 4, May 1999 (replaces educational bulletin Number 147, October 1990). Clinical management guidelines for obstetrician-gynecologists. American College of Obstetrics and Gynecology. Int J Gynaecol Obstet 1999 66 : 63 70.
10. Crowther CA, Keirse MJ. Anti-D administration in pregnancy for preventing rhesus alloimmunisation. Cochrane Database Syst Rev 2000 : CD000020.
11. Chilcott J, Lloyd JM, Wight J, Forman K, Wray J, Beverley C, et al. A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative. Health Technol Assess 2003 7 : 4.
12. Jones ML, Wray J, Wight J, Chilcott J, Forman K, Tappenden P, et al. A review of the clinical effectiveness of routine antenatal anti-D prophylaxis for rhesus-negative women who are pregnant. BJOG 2004 111 : 892 902. (Pubitemid 39223036)
13. Engelfriet CP, Reesink HW, Judd WJ, Ulander VM, Kuosmanen M, Koskinen S, et al. Current status of immunoprophylaxis with anti-D immunoglobin. Vox Sang 2003 85 : 328 37.
14. Koelewijn JM, de Haas M, Vrijkotte TG, Bonsel GJ, Van der Schoot CE. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. Transfusion 2008 48 : 1721 9.
15. Ness PM, Baldwin ML, Niebyl JR. Clinical high-risk designation does not predict excess fetal-maternal hemorrhage. Am J Obstet Gynecol 1987 156 : 154 8.
16. Sebring ES, Polesky HF. Fetomaternal hemorrhage: incidence, risk factors, time of occurrence, and clinical effects. Transfusion 1990 30 : 344 57.
17. Feldman N, Skoll A, Sibai B. The incidence of significant fetomaternal hemorrhage in patients undergoing cesarean section. Am J Obstet Gynecol 1990 163 : 855 8.
18. David M, Smidt J, Chen FC, Stein U, Dudenhausen JW. Risk factors for fetal-to-maternal transfusion in Rh D-negative women - results of a prospective study on 942 pregnant women. J Perinat Med 2004 32 : 254 7.
19. Salim R, Ben Shlomo I, Nachum Z, Mader R, Shalev E. The incidence of large fetomaternal hemorrhage and the Kleihauer-Betke test. Obstet Gynecol 2005 105 : 1039 44.
20. Health Care Insurance Board. Blood Testing in Pregnancy. Pregnancy Immunisation, Hepatitis B and Lues. The Hague : Health Care Insurance Board. National Health Inspection, 1998. [Dutch].
21. Van der Ploeg CPB, Anthony S, Rijpsta A, Verkerk PH. [Process Monitoring Pre- and Postnatal Screenings 2003]. Leiden, the Netherlands : TNO Quality of Life, 2006. [Dutch].
22. Koelewijn JM, Vrijkotte TG, Van der Schoot CE, Bonsel GJ, de Haas M. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion 2008 48 : 941 52.
23. Murray S, Knox EG, Walker W. Rhesus haemolytic disease of the newborn and the ABO groups. Vox Sang 1965 10 : 6 31.
24. Bais JMJ. Risk selection and detection: a critical appraisal of the Dutch obstetric system. Thesis, Amsterdam : University of Amsterdam, 2004, 25 pp.
25. [ http://statline.cbs.nl/StatWeb/publication/?DM-SLNL&PA= 37201&D1=0,7-22&D2=5-16&D3=(l-5)-l&VW=T ]. Accessed 19 August 2008.
26. Ulm B, Svolba G, Ulm MR, Bernaschek G, Panzer S. Male fetuses are particularly affected by maternal alloimmunization to D antigen. Transfusion 1999 39 : 169 73.
27. Mahboob U, Mazhar SB. Role of Kleihauer test in Rhesus negative pregnancy. J Coll Physicians Surg Pak 2006 16 : 120 3.
28. Pelikan DM, Scherjon SA, Mesker WE, Groot-Swings GM, Brouwer-Mandema GG, Tanke HJ, et al. Quantification of fetomaternal hemorrhage: a comparative study of the manual and automated microscopic Kleihauer-Betke tests and flow cytometry in clinical samples. Am J Obstet Gynecol 2004 191 : 551 7.
29. Bowman JM, Pollock JM. Antenatal prophylaxis of Rh isoimmunization: 28-weeks'-gestation service program. Can Med Assoc J 1978 118 : 627 30.
30. Kennedy MS, McNanie J, Waheed A. Detection of anti-D following antepartum injections of Rh immune globulin. Immunohematology 1998 14 : 138 40.
31. Rudensky B, Mazaki E, Na'amad M, Samueloff A. Lack of anti-D in women at birth following antepartum immune globulin prophylaxis. Eur J Obstet Gynecol Reprod Biol 2003 107 : 45 6.
32. MacKenzie IZ, Roseman F, Findlay J, Thompson K, Jackson E, Scott J, et al. The kinetics of routine antenatal prophylactic intramuscular injections of polyclonal anti-D immunoglobulin. BJOG 2006 113 : 97 101.
33. Denomme GA, Wagner FF, Fernandes BJ, Li W, Flegel WA. Partial D, weak D types, and novel RHD alleles among 33,864 multiethnic patients: implications for anti-D alloimmunization and prevention. Transfusion 2005 45 : 1554 60.
34. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006 24 : 1159 69.
35. Martins PN, Pratschke J, Pascher A, Fritsche L, Frei U, Neuhaus P, et al. Age and immune response in organ transplantation. Transplantation 2005 79 : 127 32.
36. MacKenzie I. Antenatal anti-D prophylaxis: one dose or two? BJM 2004 12 : 13 4.
37. MacKenzie IZ, Findlay J, Thompson K, Roseman F. Compliance with routine antenatal rhesus D prophylaxis and the impact on sensitisations: observations over 14 years. BJOG 2006 113 : 839 43.